| abstract |
The present invention relates to new derivatives of carboxylic acid amides of the formula (I) where the adjacent V and U groups form together with -CH or -CH = groups a 4-7 membered homo- or heterocyclic ring which may be interrupted by 1 to 3 identical or various heteroatoms selected from the group N and / or O and / or S and which may be substituted with 1-2 O, S or alkyl atoms; W is —CO—, —CH— or —CH (—alkyl) - group; Y is an oxygen atom, as well as a C-alkylene, C-alkynylene, cycloalkylene, aminocarbonyl, —NH—, —N (alkyl) -, —CHO—, —CH (OH) -, —OCH— group; Z is a hydrogen or halogen atom, nitro, amino, alkyl, C-Salkoxy, cyano, trifluoromethyl, hydroxyl or carboxyl group and optical antipodes or racemates and / or their pharmaceutically acceptable salts formed with acids and bases, as well as pharmaceutical compositions, containing carboxylic acid amide derivatives of formula (I) or pharmaceutically acceptable salts thereof, as active ingredients. The next object of the invention are methods for producing derivatives of carboxylic acid amides of the formula (I) and pharmaceutical production of drugs containing these compounds, as well as a treatment method using these compounds, comprising administering to a mammal in need of treatment, including humans, an effective amount / amounts of compounds of the formula (I) of the present invention as such or as a medicine. The novel carboxylic acid amide derivatives of formula (I) of the present invention are highly potent and selective antagonists of the NMDA receptor, and furthermore, most of the compounds are selective antagonists of the NR2B subtype of the NMDA |